Form 4: Medtronic Exec's Equity Vesting & Tax Withholding
Insider Transaction Report
Medtronic EVP Brett Wall reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.
Summary
- Brett A. Wall, Medtronic's EVP & President of Neuroscience, reported transactions on August 1, 2025.
- He acquired 15,249 ordinary shares through the settlement of performance-vesting restricted stock units (RSUs) granted on August 1, 2022, including earned dividend equivalents.
- Concurrently, 7,744 ordinary shares were withheld for taxes upon the settlement of these performance-vesting RSUs, at a price of $89.34 per share.
- An additional 3,850 ordinary shares were withheld for tax payments upon the vesting of other previously reported restricted stock units, also at $89.34 per share.
- Following these transactions, Brett Wall directly beneficially owns 54,937 ordinary shares.
Sentiment
Score: 5
Explanation: The filing details routine executive equity compensation vesting and associated tax-related share disposals, which are standard practice and do not indicate significant operational or financial shifts.
Positives
- Executive Brett A. Wall received 15,249 ordinary shares from the vesting of performance-based equity awards, indicating successful achievement of performance metrics.
Negatives
- A total of 11,594 ordinary shares (7,744 and 3,850) were disposed of to cover tax obligations related to the vesting of equity awards.
Stakeholder Impact
- Shareholders: Minor impact from routine equity compensation vesting and associated tax-related share disposals.
- Employees: Reflects standard executive compensation practices within the company.
Key Dates
| Date | Description |
|---|---|
| 08/01/2022 | Grant date of performance-vesting restricted stock units. |
| 08/01/2025 | Date of equity award vesting and related share transactions. |
| 08/04/2025 | Date the Form 4 was signed and filed. |
Recommendation
holdThis Form 4 filing details a routine executive compensation event involving the vesting of performance-based equity and subsequent share disposals for tax purposes. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are standard and expected for executive equity awards.
Keywords
Medtronic, MDT, Form 4, insider transaction, equity compensation, RSU, PSU, stock vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.